Meeting Banner
Abstract #4831

Does the timing of immunotherapy with stereotactic radiosurgery affect the outcome of patients with brain metastases?

Endre Grøvik1, Line Brennhaug Nilsen1, Ingrid Digernes1, Cathrine Saxhaug1, Anna Latysheva1, Oliver Geier1, Birger Breivik2, Dag Ottar Sætre3, Kari Dolven Jacobsen1, Åslaug Helland1, and Kyrre Eeg Emblem1
1Oslo University Hospital, Oslo, Norway, 2Hospital of Southern Norway, Kristiansand, Norway, 3Østfold Hospital Trust, Kalnes, Norway

The introduction of immunotherapy (IMTx) has led to a paradigm shift in the treatment of patients with metastatic cancer. Particular interest has been directed towards combining IMTx with stereotactic radiosurgery (SRS) to improve treatment response. Lately, studies have indicated that the timing of IMTx with SRS may be crucial for the patient outcome, suggesting that there is a window of opportunity to induce an optimal synergy between irradiation and immune agents. To this end, this work investigates whether the timing of IMTx with SRS affects the outcome of patients with brain metastases.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here